To explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)
Aged 18-75 years, male or female without restriction;
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1; Estimated survival time ≥ 3 months;
Histologically or cytologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC);
At least one measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1);
Histologically confirmed tumor containing small cell lung cancer components.
Medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid intervention, or any clinical evidence of active ILD.
Symptomatic or actively progressive central nervous system (CNS) metastases or leptomeningeal metastases confirmed by CT/MRI during screening and prior to radiological assessment.
Subjects requiring systemic corticosteroids or other immunosuppressive agents within 14 days before the first study drug administration. 5. Nasal/inhaled corticosteroids or physiological doses of systemic steroids (i.e., ≤10 mg prednisolone per day or equivalent physiological doses of other corticosteroids) are excluded from this restriction.
Single group
Almonertinib
DrugThird-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) options are permitted, with almonertinib mesylate selected as the first-line preference
Trastuzumab Rezetecan
DrugHER2 ADC
ORR
Click on the lead sponsor to view all of their trials.
Yongsheng Wang
Lead sponsor
Sichuan University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
